Allergan plc (NYSE:AGN) Shares Bought by Shufro Rose & Co. LLC

Share on StockTwits

Shufro Rose & Co. LLC lifted its position in shares of Allergan plc (NYSE:AGN) by 0.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 149,602 shares of the company’s stock after buying an additional 460 shares during the quarter. Allergan makes up 2.6% of Shufro Rose & Co. LLC’s holdings, making the stock its 7th largest holding. Shufro Rose & Co. LLC’s holdings in Allergan were worth $28,496,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Boltwood Capital Management lifted its stake in shares of Allergan by 5.6% during the 3rd quarter. Boltwood Capital Management now owns 5,081 shares of the company’s stock worth $967,000 after purchasing an additional 270 shares during the last quarter. Parkside Investments LLC lifted its stake in shares of Allergan by 1.8% during the 2nd quarter. Parkside Investments LLC now owns 15,845 shares of the company’s stock worth $2,830,000 after purchasing an additional 275 shares during the last quarter. Avestar Capital LLC lifted its stake in shares of Allergan by 25.1% during the 2nd quarter. Avestar Capital LLC now owns 1,483 shares of the company’s stock worth $230,000 after purchasing an additional 298 shares during the last quarter. New Jersey Better Educational Savings Trust lifted its stake in shares of Allergan by 9.4% during the 2nd quarter. New Jersey Better Educational Savings Trust now owns 3,500 shares of the company’s stock worth $584,000 after purchasing an additional 300 shares during the last quarter. Finally, Parallel Advisors LLC lifted its stake in shares of Allergan by 34.9% during the 2nd quarter. Parallel Advisors LLC now owns 1,233 shares of the company’s stock worth $205,000 after purchasing an additional 319 shares during the last quarter. 78.40% of the stock is currently owned by institutional investors and hedge funds.

In other news, Director Christopher J. Coughlin acquired 10,000 shares of Allergan stock in a transaction dated Thursday, September 6th. The stock was purchased at an average cost of $190.64 per share, for a total transaction of $1,906,400.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Joseph H. Boccuzi acquired 900 shares of Allergan stock in a transaction dated Thursday, August 30th. The stock was purchased at an average price of $190.59 per share, with a total value of $171,531.00. The disclosure for this purchase can be found here. Company insiders own 0.36% of the company’s stock.

A number of equities research analysts recently weighed in on the company. ValuEngine cut Allergan from a “sell” rating to a “strong sell” rating in a research note on Friday. Leerink Swann assumed coverage on Allergan in a research note on Monday, November 12th. They set an “outperform” rating and a $220.00 price objective for the company. Wells Fargo & Co restated a “buy” rating on shares of Allergan in a research note on Wednesday, October 31st. Cantor Fitzgerald set a $180.00 price objective on Allergan and gave the stock a “hold” rating in a research note on Monday, August 6th. Finally, Mizuho upgraded Allergan from a “neutral” rating to a “buy” rating in a research note on Friday, August 3rd. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and eighteen have issued a buy rating to the company. Allergan has a consensus rating of “Buy” and an average target price of $209.18.

Allergan stock opened at $157.39 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 0.92 and a quick ratio of 0.78. Allergan plc has a one year low of $142.81 and a one year high of $197.00. The stock has a market capitalization of $53.09 billion, a price-to-earnings ratio of 9.11, a price-to-earnings-growth ratio of 1.22 and a beta of 1.31.

Allergan (NYSE:AGN) last released its quarterly earnings results on Tuesday, October 30th. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $4.04 by $0.21. Allergan had a return on equity of 8.44% and a net margin of 14.50%. The company had revenue of $3.91 billion during the quarter, compared to analysts’ expectations of $3.89 billion. During the same period last year, the business posted $4.15 earnings per share. The firm’s revenue was down 3.0% compared to the same quarter last year. As a group, equities analysts predict that Allergan plc will post 16.49 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 14th. Stockholders of record on Tuesday, November 13th will be paid a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 1.83%. The ex-dividend date is Friday, November 9th. Allergan’s payout ratio is 17.61%.

COPYRIGHT VIOLATION WARNING: “Allergan plc (NYSE:AGN) Shares Bought by Shufro Rose & Co. LLC” was originally posted by BBNS and is the property of of BBNS. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://baseballnewssource.com/2018/11/18/allergan-plc-agn-is-shufro-rose-co-llcs-7th-largest-position/2886837.html.

About Allergan

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.

Further Reading: Systematic Risk and Investors

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.